)
)
Altimmune Investor Relations Material
Latest events
Q3 2024
Altimmune
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Altimmune Inc
Access all reports
Altimmune, Inc. engages in the development of immunotherapeutics for infectious and chronic diseases. The company focuses on the development of vaccines and therapeutics for influenza, anthrax and COVID-19. It offers HepTcell, a vaccine candidate to treat Chronic Hepatitis B; AdCOVID, which is an intranasal antigen vaccine to fight COVID-19; NasoVAX, a single dose flu vaccine; T-COVID, an intranasal immune modulating therapeutic candidate; and NasoShield, an anthrax vaccine product candidate. The company was founded by Vipin K. Garg on April 15, 2005 and is headquartered in Gaithersburg, MD.
Latest articles
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Ticker symbol
ALT
Country
🇺🇸 United States